On August 4, IDEXX Laboratories rose 6.55% in regular trading, trading at $607.91/share, with turnover of $90.58 million. The surge was driven by the company's strong Q2 earnings report released before the market open.
IDEXX Laboratories reported Q2 adjusted EPS of $4.07, surpassing the analyst consensus estimate of approximately $3.94-$3.96, representing a roughly 15% year-over-year increase from $3.53. Quarterly revenue reached $1.217 billion, exceeding the expected $1.20 billion and up from $1.11 billion a year earlier. The company also raised its full-year EPS guidance to $14.69-$14.94, up from the prior range of $14.45-$14.90, while narrowing its revenue outlook to $4.70-$4.75 billion. Both metrics exceeded analyst expectations of $14.65 EPS on $4.71 billion in revenue.
The beat follows a pattern of strong operational momentum. In Q1, revenue of $1.141 billion also topped estimates, and the company had raised full-year guidance citing higher clinical visit volumes and increased diagnostic frequency. Product innovation, including expanded fecal antigen testing for tapeworm detection and a canine lymphoma early screening panel, continues to broaden the diagnostic platform.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments